25.02.2008 ARTES and m2p-labs join forces and offer an exclusive technology combination ARTES Biotechnology GmbH (Langenfeld) and m2p-labs GmbH (Aachen) announced today the start of a long-term collaboration in clone screening and media optimisation. The two companies combine their proprietary technologies and know-how in yeast expression and high throughput fermentation. In this exclusive collaboration the two companies offer strain selection, physiological characterization and media optimization with the two yeast systems Hansenula polymorpha and Arxula adeninivorans. The combination of this high-productive expression systems and the powerful BioLector screening tool provide much more physiological data at a high throughput level in screening and early bioprocess development. Both companies are convinced that their clients will profit from this new technology offer by reduced time lines in strain and process development, the availability of new carbon sources and more productive clones and culture conditions. 14.01.2008 ARTES and Minapharm sign long-term strategic development agreement Langenfeld and Cairo, January 14, 2008 / b3c newswire / ARTES Biotechnology, which is specialized in recombinant protein production from yeast expression systems, and Rhein Minapharm Biogenetics, a subsidiary of Minapharm SAE jointly announced the start of a strategic collaboration to develop three therapeutic proteins. Financial details were not disclosed. For further information please choose the link below: http://www.b3c.de/php/popup.php?id=98 30.11.2007 New Technology Launch ARTES is proud to announce the launch of new expression technologies - Arxula and the Wide Range Expression Vector System. Information about these technologies and the offer can be found on the newly designed webpages. 08.10.2007 Exclusive Cooperation between ARTES and IPK ARTES Biotechnology GmbH expands technology platform Obviously the new offices and laboratories in Langenfeld (near Dusseldorf) inspire ARTES´ business and scientific development. Achieving notable success with the Hansenula technology for years, the biotech company has now concluded an exclusive cooperation with the internationally renowned Leibniz Institute of Plant Genetics and Crop Plant Research (IPK) in Gatersleben. „The aim is a joint research and marketing of a new yeast expression technology“, explains Dr. Melanie Dröttboom, in charge of Business Development at ARTES Biotechnology GmbH. „With the new collaboration we are able to expand our offer and we win an important academic research partner “, says Dröttboom. Prof. Dr. Gotthard Kunze, head of the department of Molecular Cell Biology, stands for the new agreement on behalf of the IPK Gatersleben. „This cooperation helps us to broaden and strengthen the research on the yeast Arxula adeninivorans “, states Prof. Dr. Kunze. ARTES Biotechnology concentrates on applied research and on marketing. 02.10.2007 Biotechnica 2007 ARTES is exhibiting at the Biotechnica 2007 in Hannover. You can visit us in hall 9 booth 16 from October 9 to 11. We look forward meeting you in Hannover! Biotechnica homepage 27.08.2007 ARTES at NEW LOCATION On August 27, 2007, ARTES has moved its laboratories and offices to Langenfeld, near Düsseldorf. The new location provides with 850 sqm more than twice the space as before. With this step ARTES is now optimally equipped for the increasing number of contract R&D projects and own long-term research. NEW CONTACT DETAILS: Elisabeth-Selbert-Str. 9 40764 Langenfeld P: +49 (0)2173 27587-0 F: +49 (0)2173 27587-77 17.07.2007 Important Step for Artes Growing international reputation „We are looking forward to work in an international team“, says Dr. Melanie Dröttboom, in charge of Business Development of the Artes Biotechnology GmbH. The Biotech company in Erkrath (near Düsseldorf) has been confirmed the „development of an aptamer-based microarray for the detection of multiple cancer-biomarkers in serum”. This project will be granted with an amount of round about four million Euro. Apart from Artes Biotechnology GmbH there are six other companies from Spain, Germany, Israel and France involved in this transnational program „Eurotransbio“, supported by the German national BMBF (German Ministry of Education and Research). „This three year cooperation with our international partners enables us to enhance our skills and gives us the chance to enter new markets with a diagnostic product“, states Dr. Dröttboom. 18.12.2006 New European Patent Granted ARTES today announces the grant of the European patent on increasing recombinant protein secretion in yeast by co-expression of Calnexin, a protein responsible in intracellular quality control and sorting. In extensive studies, ARTES could show that overexpression of Calnexin results in significant increase of protein secretion, independent of the nature of product or the size of fermentation. This technology further boosts the already high level of protein secretion in Hansenula, but also in other yeast species. The Calnexin patent is co-owned by ARTES Biotechnology GmbH and Rhein Biotech GmbH. 19.06.2006 PROTEO Biotech AG and ARTES Biotechnology GmbH: Strategic alliance for marketing of Elafin Kiel - Erkrath, June 19, 2006. PROTEO Biotech AG, a wholly owned subsidiary of PROTEO Inc./USA (OTCBB: PTEO; WKN: 925981) has signed a cooperation agreement with ARTES Biotechnology GmbH. The aim of the agreement is the marketing of Elafin, the lead product of PROTEO Biotech AG/PROTEO Inc., in India, Egypt and Argentina. In 2004 PROTEO acquired the exclusive license from ARTES to produce recombinant Elafin using the yeast strain Hansenula polymorpha. PROTEO`s CEO Birge Bargmann stated: “Because of the extensive foreign contacts of ARTES, we expect a breakthrough in the application of Elafin, especially in view of faster regulatory approval procedures.” Both partners regard the intensification of their collaboration as a strategic alliance in which ARTES will initiate and supervise Elafin projects in the intended foreign markets. PROTEO is the first company in Germany, which after having received approval from the German Federal Institute for Drugs and Medical Products (BfArM), has successfully conducted a Phase I clinical trial on humans using a compound manufactured with ARTES` Hansenula-technology. Proteo Biotech AG 14.06.2006 ARTES Biotechnology GmbH and ProteoNic BV start research collaboration Today ARTES Biotechnology GmbH, Germany, and ProteoNic B.V., The Netherlands, announce the start of their research collaboration. Both companies will join forces to investigate on the application of ProteoNic´s proprietary technology for enhancement of gene expression in the methylotrophic yeast Hansenula polymorpha, offered by ARTES. 23.04.2006 Forthcoming events ARTES will present the technology and service offer plus latest achievements and developments at: BIOFINE, Barcelona, on May 4th 2006 and ACHEMA, Frankfurt, on May 17th 2006. To arrange for direct meetings please contact: info@artes-biotechnology.com 02.01.2006 NEW ADRESS Effective January 1st, 2006, ARTES has shifted its operations to a new location in: 40699 Erkrath, Germany Max-Planck-Str. 15a. The new, appr. 400 square meter facility combines now offices and laboratories at one site, increasing ARTES´ capacities and further improving our services. 14.10.2005 Bio-fuel production under ARTES´ license ARTES Biotechnology GmbH, Germany and IOGEN Corporation, Canada have concluded a license agreement regarding the use of yeast to ferment xylose to ethanol. Under this license, ARTES grants the rights to its xylose reductase/xylitol dehydrogenase patent family for the commercial production of bio-ethanol from renewable resources. Dr. Jeffrey Tolan, IOGEN Corporation: "Iogen is the leader in ethanol production from cellulosic biomass. We have been producing fuel ethanol from wheat straw in our demonstration plant in Ottawa, Canada for the past 18 months. The agreement with Artes is an important part of the unique yeast technology that we are using in our plant.” Dr. Michael Piontek, ARTES Biotechnology GmbH: "The agreement with IOGEN is a strong proof for the impact of ARTES` technologies in the area of White Biotechnology, especially on the use of renewable resources. In addition to feed/food enzymes produced and marketed from the Hansenula technology, our xylose fermenting yeast technology is now applied in bio-fuel production." IOGEN Homepage 31.08.2005 ARTES and NOVOZYMES announce collaboration ARTES Biotechnology GmbH, Germany and Novozymes A/S, Denmark today announce the start of a mid-term collaboration on the development of recombinant yeast strains. Under this agreement, ARTES will evaluate its Hansenula expression system for the production of different Novozymes´ target proteins. 15.08.2005 Visit us at Biotechnica, Hannover 18-20 October 2005 booth #D24 Biotechnica 2005 16.06.2005 New patent family Artes Biotechnology GmbH today announces the complete acquisition of the international patent family on a Universal Blood Test Tube – UBT. This hirudinized blood withdrawal tube is the world-wide first approach for the determination of almost all measurement parameters in blood analysis in a single test tube. This tube allows automated and simultaneous analysis of haematological and clinico-chemical parameters in whole blood samples. The recombinant Hirudin used for the coating of the UBT is supplied by ARTES and derived from the patent protected expression system Hansenula polymorpha. The UBT is the first application of a Hansenula derived protein in a medical device. Complete UBT info 31.05.2005 BIO 2005, Philadelphia Visit us at booth #627-42 within the Germany Pavilion or contact us directly for a personal meeting! Go to BIO website 10.05.2005 Artes and IMEnz announce collaboration on microbial expression systems Düsseldorf/Groningen: A unique set of microbial hosts for gene expression has become available by the collaboration agreement between the biotech companies Artes Biotechnology (Düsseldorf, Germany) and IMEnz Bioengineering Groningen, The Netherlands). To expand the range of different microbial expression systems Artes and IMEnz agreed on a service, research and development collaboration. Artes will combine its “System Screening Service” with IMEnz` “Genome Exploration Toolbox (GET)” to offer a well-balanced selection of eukaryotic, gram-positive and gram-negative bacteria as hosts for the production of a variety of different proteins. The joint service allows a highly efficient simultaneous screening in the most relevant microbial expression systems to find the host ideally suited expressing client’s gene of interest. GET technology IMEnz Bioengineering 04.03.2005 Artes and AC Biotec join forces in small scale cultivation and expression technology Today Artes Biotechnology GmbH and AC Biotec GmbH announce a collaboration agreement in the area of small scale cultivation and expression technologies using the companies´ proprietary technologies and genuine competencies. Within the collaboration AC Biotec will provide its core competency in the miniaturization of microbial cultivation. ARTES adds the long-term experience in contract R&D in the field of recombinant gene expression, specifically in the proven yeast system Hansenula polymorpha. Artes Biotechnology GmbH, a profitable German biotech company, is offering R&D services for recombinant strain development in microbial expression systems. Artes` customers include multinational players such as DSM Nutritional Products (previously Roche), Danisco and Fuji as well as small and middle sized companies. AC Biotec GmbH is a service provider in the field of bioprocess development, contract manufacturing and technology consulting. The core competence of AC Biotec includes the application of small-scale culture systems and the scaling of bioprocesses in between these systems and technical-scale stirred bioreactors. AC Biotec 31.01.2005 FUJI and ARTES Biotechnology announce collaboration Düsseldorf/Tilburg, 31st. January 2005; Today FUJI Photo Film B.V. and ARTES Biotechnology GmbH announce a collaboration for the development of Hansenula based production strains for a special biopolymer. Launched products derived from the superior yeast Hansenula polymorpha include food ingredients such as Hexose Oxidase as well as Hepatitis B vaccines, Insulin and Interferon alpha. In the project with FUJI ARTES contributes its long experience in production strain generation and fermentation. Dr. Michael Piontek: “For ARTES it is the first step into a completely new market segment and therefore the cooperation opens novel possibilities.” Dr. Henk van Urk: “FUJI Photo Film B.V. is determined to commercialise recombinant gelatins for pharmaceutical applications. As a host system we make use of both Pichia pastoris and Hansenula polymorpha. In order to be able to exploit both systems to the maximum, collaborations are needed with renowned experts in the field of yeast expression systems. Already partnership was established with Rijks Universiteit Groningen (RUG) and now we are glad to announce that we could agree upon a collaboration with ARTES Biotechnology.” 01.12.2004 Proteo Biotech AG signs exclusive License- and Collaboration agreement with Artes Proteo Biotech is producing its Elafin with the patent protected yeast strain Hansenula polymorpha on a recombinant basis for a world market. Proteo has signed an exclusive License- and Collaboration agreement with Artes Biotechnology. „This agreement will enable us to produce Elafin, in a large scale, very economically by using the in-licensed yeast Hansenula polymorpha as an high performance expression system. The License- and Collaboration Agreement is an important milestone on our way to world markets and a sustainable development of the company“, so Walter J. Thomsen, CEO of Proteo. „The commercial use of the Hansenula Technology by Proteo is an additional confirmation for the safety and efficiency of our expression system“, so Dr. Michael Piontek, CEO of Artes Biotechnology. For more information on Elafin please visit http://www.proteo.de 18.10.2004 New Scientific Board Member We are proud to welcome our new Scientific Board Member: Prof. Andrei A. Sibirny, Director of Institute of Cell Biology, NAS of Ukraine. Prof. Sibirny - one of the leading scientists in Hansenula research - will support Artes Biotechnology as consultant and network partner. 07.09.2004 Hansenula polymorpha Worldwide Network 2004 Meet Artes at the third Hansenula polymorpha Worldwide Network, 26th - 29th September 2004, Sardinia, Italy. Presentation by Dr. Adelheid Degelmann, Senior Scientist: Secreted expression of bacterial alginate epimerase in H. polymorpha. For further information please contact us! 08.07.2004 Artes at the Annual SIM Meeting 2004 Artes is glad to host a special session on Hansenula & Pichia: Methylotrophic yeasts for therapeutic proteins and industrial enzymes July 25-29, 2004 Anaheim Marriott, CA For further information please contact us or visit Society of Industrial Microbiology 01.07.2004 Artes announces implementation of Scientific Board To continuously strengthen our technology and know-how in recombinant microbial protein production, we have established a Scientific Board of renowned scientists. We are proud to welcome our founder members: - Prof. Cornelis P. Hollenberg; Head of Institute of Microbiology, Heinrich-Heine-University Düsseldorf, Founder of Rhein Biotech GmbH - Prof. Gotthard Kunze; Institut für Pflanzengenetik und Kulturpflanzenforschung Gatersleben - Dr. Kantcho Lyubenov Lahtchev; Institute of Microbiology, Department of Genetics, Bulgarian Academy of Sciences